Business Wire

TX-MARY-KAY

12.1.2023 22:22:41 CET | Business Wire | Press release

Share
Mary Kay Inc. Company-Sponsored Foundations Give Millions Supporting Women's Causes Around the World

Throughout 2022, iconic beauty brand Mary Kay—along with its company-sponsored foundations—gave more than 3 million dollars to support women’s causes around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005756/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Female entrepreneurs in Chuxiong, Yunnan Province increased their income and helped preserve the Yunnan Embroidery cultural industry thanks to Mary Kay Women’s Entrepreneurship Program. (Photo: Mary Kay Inc.)

When Mary Kay Ash, legendary businesswoman and philanthropist, opened her business in 1963, she dreamed of empowering women internationally through entrepreneurship, innovation, hard work, and giving back. Nearly 60 years later, Mary Kay employees, Independent Beauty Consultants, and members of the global community keep her dream alive through generous contributions to four company-sponsored foundations delivering impactful support to women and their families in need.

The full foundation reports can be viewed here. Here’s what they were up to in 2022:

Cancers Affecting Women

  • In the U.S., the Mary Kay Ash Foundation (MKAF) funded 37 cancer researchers conducting groundbreaking research against cancers affecting women.
  • 43% of MKAF cancer research projects are led by women; 100% of clinical trials are women-led.
  • MKAF funded nearly $1.7 million in grants for cancers affecting women.

Gender-based Violence

  • MKAF funded nearly $1.4 million in grants supporting services for women survivors of domestic violence.
  • MKAF supported 4 local domestic violence shelters in North Texas providing women seeking help with vital resources and safety.
  • In collaboration with Mary Kay, MKAF supported global partners committed to end violence against women and girls, including CARE and UN Trust Fund. Together, MKAF partners completed over 550 projects around the world.
  • Instituto Mary Kay and Mary Kay Brazil received the Silver Award for the Red Cross Campaign “Campanha Sinal Vermelho Contra a Violência Doméstica” at ABEVD Associação Brasileira das Empresas de Venda Direta (Brazil DSA) Anual Congress.
  • In Canada, the Mary Kay Ash Charitable Foundation awarded $10,000 each to 16 domestic violence shelters across Canada, totaling $160,000.

Women and Their Families

Mary Kay China and its company-sponsored programs and fund have provided support through the following efforts:

  • Mary Kay Women’s Entrepreneurship Program
    • In cooperation with China Women’s Development Foundation, interest-free revolving loans were provided to four women entrepreneur initiatives in the provinces of Heilongjiang, Ningxia, and Jilin. The initiatives directly benefited 133 women by increasing their annual per capita income by RMB 20,000 yuan.

  • Young Women’s Future Fund
    • In cooperation with Adream Foundation, the Young Women’s Future Fund remaining balance will be used to build four Mary Kay Dream Classrooms in Jiangxi to enhance girls’ literacy education.

  • Mary Kay China Charity Program
    • Since March 2022, the Mary Kay China Charity Program has allocated 1,049,800 yuan to provide protective materials and living supplies to 73 communities in 15 cities as a result of the COVID-19 epidemic.
    • Thanks to the joint efforts of Mary Kay China and its Beauty Consultants, the "Smile 1000" project raised funds for 112 cleft-lip repair surgeries in 2022. To date, Mary Kay China has raised funds for 991 surgeries and is on track to achieve the goal of 1,000 smiles in 2023.
    • By May, 1,391 Beauty Consultant volunteers had delivered 331 beauty lessons to 9,147 women.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005756/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye